US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Sionna Therapeutics (SION) Six Month Summary: Hot Start, Cold Reality, and a Strong Spring Rebound

Sionna Therapeutics, Inc. (SION): Biotech for Patients with Cystic Fibrosis Filed for IPO

Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO

Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome

IPOs and Secondary Offerings

Equity Capital Markets

Sionna Therapeutics / Equity Capital Markets

<ul>
<li>Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.</li>
<li>The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.</li>
<li>The IPOs that are more apt to see "follow-through" in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria. </li>
</ul>


Biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis opened its IPO 39% above issue.
The transaction was upsized from 8.8mm shares to 10.6mm shares and priced at the high-end of the range.
The IPOs that are more apt to see "follow-through" in the aftermarket are those with product candidates in later stage. This IPO does not meet that criteria. 


Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut